Macrolides are defined chemically by a large macrocyclic lactone ring, typically a fourteen-, fifteen- or sixteen-membered ring decorated with sugars and other substituents that are essential for biological activity. The prototype of the class, erythromycin, was first isolated as a natural product from Streptomyces species, soil-dwelling bacteria renowned for their extraordinary capacity to produce bioactive secondary metabolites. The macrocyclic lactone scaffold is assembled inside the producing organism by modular polyketide synthase enzymes, gigantic multi-protein assembly lines that stitch together small carboxylic acid building blocks in a stepwise fashion. This biosynthetic logic, in which each module of the polyketide synthase corresponds to one elongation cycle, has not only fascinated biochemists for decades but also provided the synthetic blueprint for engineered and semisynthetic derivatives with improved pharmacological properties.

The clinical success of macrolides rests on a deceptively simple molecular mechanism: the inhibition of bacterial protein synthesis. Structural and biochemical studies have shown that macrolides bind within the nascent peptide exit tunnel of the bacterial 50S ribosomal subunit, the channel through which a growing polypeptide chain must pass as it emerges from the ribosome’s catalytic core. By parking themselves in this tunnel, macrolides physically obstruct elongation of the nascent chain, halting translation and ultimately depriving the bacterium of the proteins it needs to survive and replicate. The precise binding site involves nucleotides of the 23S ribosomal RNA, and the position of the drug within the tunnel determines which peptide sequences can still be synthesized and which are blocked. This mechanism explains why macrolides are bacteriostatic against most organisms, arresting growth rather than rapidly killing cells, although certain derivatives display more bactericidal behavior against specific pathogens.

That mechanism has proven clinically valuable across a remarkable range of infections. Macrolides are among the most commonly prescribed outpatient antibiotic classes in the world, and physicians reach for them to treat community-acquired pneumonia, sexually transmitted diseases including infections caused by Chlamydia and other atypical pathogens, and a variety of gastrointestinal infections. Their favorable oral bioavailability, extensive tissue penetration and accumulation inside cells such as macrophages make them particularly attractive for intracellular pathogens, while their relatively mild side-effect profile compared with older broad-spectrum agents has cemented their place in primary care. Successive generations of semisynthetic macrolides, including the second-generation azithromycin and clarithromycin and the third-generation telithromycin and ketolides, were developed specifically to overcome early resistance and to improve acid stability and pharmacokinetics.

Yet the review emphasizes that clinical successes have been tempered by a growing list of failures, and it organizes these failures into mechanistically distinct categories. The first and most visible is true resistance, the genetically encoded, heritable capacity of a bacterium to grow at antibiotic concentrations that would normally be inhibitory. For macrolides, the dominant resistance mechanism is enzymatic modification of the ribosomal target itself. Methyltransferases encoded by erm genes methylate a specific adenine residue in the 23S rRNA within the drug binding site, sterically blocking macrolide binding and often producing cross-resistance to other antibiotics that target the same ribosomal region, such as lincosamides and streptogramins, a phenotype known as the MLSb resistance pattern. Efflux pumps constitute a second major mechanism: membrane transporters of the Mef and Msr families actively pump the drug out of the cell, lowering the intracellular concentration below therapeutic thresholds. A third mechanism involves enzymatic inactivation, in which phosphotransferases, glycosyltransferases or esterases chemically modify or cleave the macrolactone ring or its sugar substituents. Finally, mutations in the 23S rRNA or in ribosomal proteins can alter the binding pocket directly, a route that becomes particularly important in organisms with few ribosomal RNA operons.

The review then turns to a subtler and less clinically appreciated phenomenon: antibiotic tolerance. Unlike resistance, tolerance does not allow bacteria to proliferate in the presence of the drug. Instead, tolerant cells survive transient exposure to otherwise lethal concentrations without growing, resuming normal division once the antibiotic is removed. Tolerance is frequently linked to slow growth, dormancy, nutrient limitation, stress responses and the formation of persister cells, subpopulations within an apparently susceptible culture that remain metabolically quiescent and thereby evade the bacteriostatic and bactericidal consequences of translation arrest. Because macrolides are primarily bacteriostatic and rely on active bacterial growth to express their full effect, metabolically dormant cells are disproportionately able to survive macrolide treatment. Tolerance, the authors stress, does not raise the minimum inhibitory concentration measured in standard susceptibility tests, which helps explain why it can go undetected in the laboratory while still compromising treatment outcomes in patients, particularly in chronic and biofilm-associated infections where nutrient gradients and slow growth are the norm.

The third barrier, and arguably the most consequential for the future of the class, is the limited activity of macrolides against Gram-negative bacteria. Gram-negative organisms, including the notorious Enterobacterales and non-fermenting pathogens such as Pseudomonas aeruginosa, are shielded by an outer membrane that functions as a molecular sieve. The lipid bilayer of this membrane excludes hydrophobic molecules, while embedded porin channels admit only small, water-soluble compounds, and macrolides, which are large, bulky and lipophilic, fit poorly through these gates. Compounding this physical barrier is the formidable armory of efflux pumps that Gram-negative bacteria maintain, transporters that recognize and expel macrolides from the periplasm and cytoplasm before the drugs can reach the ribosome in sufficient quantities. As a result, even though the ribosomal target inside Gram-negative bacteria is fundamentally the same as in susceptible Gram-positive species, the drug rarely arrives at its destination at concentrations high enough to inhibit translation. This pharmacological inaccessibility has largely excluded macrolides from the treatment of infections caused by multidrug-resistant Gram-negative pathogens, precisely the organisms for which new therapeutic options are most urgently needed.

The central argument of the review is that these barriers need not be permanent. The authors survey recent work aimed at identifying adjuvant compounds, molecules that are co-delivered with macrolides to disable the defenses that limit their activity. Adjuvants can act at several points of attack. Inhibitors of efflux pumps can cripple the transporters responsible for expelling the antibiotic, restoring intracellular concentrations to effective levels; this strategy is particularly relevant for Gram-negative pathogens whose efflux systems are major contributors to intrinsic macrolide resistance. Permeabilizers, including certain membrane-active agents, can transiently disrupt the outer membrane, widening the path through which the bulky macrolide molecule must pass to reach the periplasm and cytoplasm. Other adjuvant concepts target tolerance rather than resistance, for example by interfering with stress responses or metabolic states that keep persister cells dormant, thereby re-sensitizing these subpopulations to translation arrest. Combinations of macrolides with compounds that potentiate ribosomal binding or block protective modification of the target have also been explored. The review highlights that adjuvant strategies carry the additional appeal of extending the usable lifespan of existing drugs, sidestepping some of the cost and timeline pressures that have historically slowed the development of entirely new antibiotic scaffolds.

Underlying all of these efforts is the sobering epidemiological context. Macrolide resistance has climbed steadily worldwide, driven in part by the sheer volume of outpatient prescribing and by macrolide usage in agriculture, and resistance determinants such as erm and mef genes now circulate readily among clinical isolates and commensal organisms alike. Azithromycin resistance in Neisseria gonorrhoeae and in Salmonella serovars has become a particular concern, narrowing therapeutic options for diseases that were once trivially treatable. At the same time, the pipeline of new antibiotics active against Gram-negative bacteria remains thin, and the pharmaceutical industry’s retreat from antibiotic development has left clinicians increasingly dependent on older drug classes, their derivatives and their combinations. In this landscape, a rigorous re-examination of the macrolide class is both timely and pragmatic.

What emerges from the review is a picture of a drug class whose core mechanism is sound and whose clinical niche is secure, but whose full potential has been artificially constrained by cellular barriers and microbial ingenuity that are, in principle, pharmacologically addressable. The path forward proposed by Aulia, Jung, Kronenberg and their colleagues is not a single breakthrough but a coordinated campaign: better structural understanding of ribosome binding across resistant and Gram-negative targets, systematic screening for adjuvants that dismantle efflux and permeability barriers, deeper investigation of the metabolic determinants of tolerance, and careful clinical evaluation of combination regimens that can translate laboratory synergy into patient benefit. If those efforts succeed, one of the oldest and most trusted antibiotic families in medicine may yet regain relevance against pathogens that currently lie beyond its reach, offering a template for how rational combination therapy can rejuvenate established drugs in the era of antimicrobial resistance.

Bacterial persisters are a subpopulation of cells capable of entering a dormant-like state, which renders them highly tolerant to antibiotic treatments without genetic resistance. Unlike resistant mutants, persisters do not grow in the presence of antibiotics but lie in a reversible dormant state, enabling them to “wake up” once the drug pressure lifts. The molecular basis regulating this phenotypic switch has long been enigmatic, hampering attempts to develop effective strategies to eradicate persistent infections. The discovery of a shared alarmone–GTP switch marks a significant leap in decoding the biochemical signals orchestrating this process.

At the heart of this mechanism lies the alarmone—a small signaling molecule structurally related to guanosine nucleotides—that is synthesized in response to cellular stress. Alarmones, notably (p)ppGpp, orchestrate the ‘stringent response’ governing bacterial adaptation to nutritional starvation and other environmental stresses. This study reveals that alarmones do not act in isolation but form an integrated regulatory module with GTP, the universal energy and signaling nucleotide, to decisively control entry into the persister state. The intricate balance between alarmone accumulation and GTP levels tunes the bacterial physiological state, functioning as a biochemical toggle.

Previous research had hinted at the involvement of alarmones in persistence, yet the definitive role and the underlying molecular crosstalk with central metabolic nucleotides such as GTP remained unclear. Fung and colleagues employed cutting-edge biochemical and genetic techniques across several model organisms, including Escherichia coli and Pseudomonas aeruginosa, to delineate the dynamics of alarmone and GTP pools during stress-induced persistence. Their findings demonstrate that an increase in alarmone levels coincides with a drop in GTP concentration, triggering a metabolism slowdown that facilitates persister formation.

By reconstructing bacterial metabolic networks under controlled perturbations, the researchers unveiled a feedback loop where alarmone synthesis leads to GTP depletion, which in turn modulates ribosomal activity, DNA replication, and other critical cellular processes. This metabolic throttling plunges the cell into a quiescent state that antibiotic compounds find difficult to penetrate or effectively target. Notably, the alarmone–GTP switch is shared across multiple bacterial species, highlighting its evolutionary conservation as a universal persistence module.

In mechanistic terms, alarmone molecules bind and inhibit enzymes involved in GTP synthesis, thereby lowering the intracellular GTP pool. This reduction slows down GTP-dependent processes essential for active cell growth and replication. The persister phenotype emerges as the cell adapts to these metabolic changes, engaging stress tolerance pathways and molecular chaperones that mitigate damage during dormancy. Once the stress subsides and alarmone levels diminish, GTP concentration recovers, allowing cells to exit persistence and resume proliferation—essentially a reversible on/off switch.

This paradigm-shifting discovery carries profound clinical significance. Persistent infections, such as those caused by Mycobacterium tuberculosis, are notoriously recalcitrant to antibiotic treatment, often necessitating prolonged therapy. Understanding the alarmone–GTP switch unveils new molecular targets that could, in theory, disrupt persister cell formation or prematurely force “awakening,” rendering bacterial populations more susceptible to existing antibiotics. Drug development efforts could focus on modulating enzymes governing alarmone synthesis or GTP metabolism as a strategy to tackle chronic and relapsing infections.

Beyond clinical microbiology, these insights ripple through microbial ecology and biotechnology. Persister formation influences biofilm dynamics, bacterial survival in fluctuating environments, and resilience against phage attacks. Synthetic biology applications may leverage this regulatory module to engineer bacterial strains with tunable dormancy states for industrial biosynthesis or bioremediation, enhancing control over microbial lifecycle and productivity.

Critically, the methodology employed merges state-of-the-art metabolomic profiling with single-cell analysis, allowing the team to quantify alarmone and nucleotide levels with unparalleled resolution. Fluorescent biosensors tracked metabolic shifts in real time, exposing heterogeneity within bacterial populations that static bulk measurements obscure. These technological advances enabled the identification of transient subpopulations poised on the edge of persistence, revealing a spectrum rather than a binary dormant/active state.

Furthermore, genetic perturbations disrupting alarmone synthesis enzymes such as RelA/SpoT homologs resulted in attenuated persister formation, confirming the central regulatory role of these molecules. Complementary mutations preventing GTP depletion similarly reduced persistence frequency, underscoring the necessity of both components in the switch mechanism. These results were reproducible across gram-negative and gram-positive model systems, suggesting a broadly conserved evolutionary strategy.

The conceptual framework emerging from this work integrates metabolic signaling with phenotypic heterogeneity, providing a model where environmental stress modulates alarmone synthesis, which in turn re-calibrates GTP pools and metabolic enzymes, driving cells into reversibly dormant persister states. This framework offers fertile ground for future investigations probing cross-talk with other stress responses, including toxin-antitoxin systems and quorum sensing networks, to build a holistic picture of persistence regulation.

This research also challenges previous notions that persistence is a stochastic and uncoordinated tolerance mechanism. Instead, it paints persister formation as a tightly governed, evolutionarily optimized response encoded at the metabolic and signaling nexus. Such precision control ensures bacterial populations produce persisters only as necessary, balancing survival advantage with fitness costs associated with dormancy.

As antibiotic resistance continues to escalate globally, understanding and targeting persistence pathways is imperative. This study’s elucidation of the alarmone–GTP switch not only fills a mechanistic void but also inspires new therapeutic avenues. Should molecules be discovered or designed capable of manipulating this switch, they could transform infection treatment paradigms, potentially reducing therapy durations and preventing relapses that plague current medical approaches.

The implications extend into diagnostics as well. Biosensors detecting alarmone-GTP ratios or persister markers could inform clinicians in real time about the emergence of antibiotic tolerance within patient infections, enabling adaptive treatment regimens tailored to combat persistence before it manifests clinically. Such precision diagnostics would represent a leap forward in managing hard-to-treat bacterial diseases.

In conclusion, the revelation of a shared alarmone–GTP switch as the keystone controlling bacterial persister formation constitutes a milestone in microbiology. By linking metabolic signaling with phenotypic outcomes, Fung et al. have unraveled a conserved molecular toggle central to bacterial survival strategies. This discovery not only deepens fundamental biological understanding but also opens exciting new horizons for combating persistent infections, a looming global health threat. The prospect of therapeutically targeting this switch heralds a promising avenue towards overcoming bacterial persistence and safeguarding antibiotic efficacy for future generations.

Subject of Research: Bacterial persistence and the regulatory mechanism controlling persister cell formation via an alarmone–GTP molecular switch.

Article Title: A shared alarmone–GTP switch controls persister formation in bacteria.

Article References:
Fung, D.K., Barra, J.T., Yang, J. et al. A shared alarmone–GTP switch controls persister formation in bacteria. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02015-6

Image Credits: AI Generated